

2004

## SEQUENCE LISTING

TRADE  
2004  
> AURELIUM BIOPHARMA INC.

<120> VIMENTIN DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR  
MULTIDRUG RESISTANT NEOPLASTIC DISEASE

<130> 112418.147US

<140> 10/736,889

<141> 2003-12-15

<150> 60/433,480

<151> 2002-12-13

<160> 5

<170> PatentIn Ver. 3.2

<210> 1

<211> 466

<212> PRT

<213> Homo sapiens

<400> 1

Met	Ser	Thr	Arg	Ser	Val	Ser	Ser	Ser	Ser	Tyr	Arg	Arg	Met	Phe	Gly
1				5					10					15	

Gly	Pro	Gly	Thr	Ala	Ser	Arg	Pro	Ser	Ser	Ser	Arg	Ser	Tyr	Val	Thr
			20					25					30		

Thr	Ser	Thr	Arg	Thr	Tyr	Ser	Leu	Gly	Ser	Ala	Leu	Arg	Pro	Ser	Thr
		35					40					45			

Ser	Arg	Ser	Leu	Tyr	Ala	Ser	Ser	Pro	Gly	Gly	Val	Tyr	Ala	Thr	Arg
	50					55					60				

Ser	Ser	Ala	Val	Arg	Leu	Arg	Ser	Ser	Val	Pro	Gly	Val	Arg	Leu	Leu
65					70					75					80

Gln	Asp	Ser	Val	Asp	Phe	Ser	Leu	Ala	Asp	Ala	Ile	Asn	Thr	Glu	Phe
			85						90					95	

Lys	Asn	Thr	Arg	Thr	Asn	Glu	Lys	Val	Glu	Leu	Gln	Glu	Leu	Asn	Asp
		100					105						110		

Arg	Phe	Ala	Asn	Tyr	Ile	Asp	Lys	Val	Arg	Phe	Leu	Glu	Gln	Gln	Asn
	115						120					125			

Lys	Ile	Leu	Leu	Ala	Glu	Leu	Glu	Gln	Leu	Lys	Gly	Gln	Gly	Lys	Ser
130						135					140				

Arg	Leu	Gly	Asp	Leu	Tyr	Glu	Glu	Glu	Met	Arg	Glu	Leu	Arg	Arg	Gln
145					150					155					160

Val	Asp	Gln	Leu	Thr	Asn	Asp	Lys	Ala	Arg	Val	Glu	Val	Glu	Arg	Asp
				165					170						175



Asn Leu Ala Glu Asp Ile Met Arg Leu Arg Glu Lys Leu Gln Glu Glu  
180 185 190

Met Leu Gln Arg Glu Glu Ala Glu Asn Thr Leu Gln Ser Phe Arg Gln  
195 200 205

Asp Val Asp Asn Ala Ser Leu Ala Arg Leu Asp Leu Glu Arg Lys Val  
210 215 220

Glu Ser Leu Gln Glu Glu Ile Ala Phe Leu Lys Lys Leu His Glu Glu  
225 230 235 240

Glu Ile Gln Glu Leu Gln Ala Gln Ile Gln Glu Gln His Val Gln Ile  
245 250 255

Asp Val Asp Val Ser Lys Pro Asp Leu Thr Ala Ala Leu Arg Asp Val  
260 265 270

Arg Gln Gln Tyr Glu Ser Val Ala Ala Lys Asn Leu Gln Glu Ala Glu  
275 280 285

Glu Trp Tyr Lys Ser Lys Phe Ala Asp Leu Ser Glu Ala Ala Asn Arg  
290 295 300

Asn Asn Asp Ala Leu Arg Gln Ala Lys Gln Glu Ser Thr Glu Tyr Arg  
305 310 315 320

Arg Gln Val Gln Ser Leu Thr Cys Glu Val Asp Ala Leu Lys Gly Thr  
325 330 335

Asn Glu Ser Leu Glu Arg Gln Met Arg Glu Met Glu Glu Asn Phe Ala  
340 345 350

Val Glu Ala Ala Asn Tyr Gln Asp Thr Ile Gly Arg Leu Gln Asp Glu  
355 360 365

Ile Gln Asn Met Lys Glu Glu Met Ala Arg His Leu Arg Glu Tyr Gln  
370 375 380

Asp Leu Leu Asn Val Lys Met Ala Leu Asp Ile Glu Ile Ala Thr Tyr  
385 390 395 400

Arg Lys Leu Leu Glu Gly Glu Glu Ser Arg Ile Ser Leu Pro Leu Pro  
405 410 415

Asn Phe Ser Ser Leu Asn Leu Arg Glu Thr Asn Leu Asp Ser Leu Pro  
420 425 430

Leu Val Asp Thr His Ser Lys Arg Thr Phe Leu Ile Lys Thr Val Glu  
435 440 445

Thr Arg Asp Gly Gln Val Ile Asn Glu Thr Ser Gln His His Asp Asp  
450 455 460

Leu Glu  
465

<210> 2  
 <211> 1766  
 <212> DNA  
 <213> Homo sapiens

<400> 2  
 cgcgccaccg ccgcccgcga ggccatcgcc accctccgca gccatgtcca ccagggtccgt 60  
 gtccctcgcc tcctaccgca ggatgttcgg cgcccgggc accgcgagcc ggccgagctc 120  
 cagccggagc tacgtgacta cgtccacccg cacctacagc ctgggcagcg cgtgcgccc 180  
 cagcaccagc cgcagcctct acgcctcgtc cccgggcggc gtgtatgcca cgcgctcctc 240  
 tgccgtgcgc ctgcccagca gcgtgcccgg ggtgcggctc ctgcaggact cgggtggactt 300  
 ctgcgtggcc gacgccatca acaccgagtt caagaacacc cgcaccaacg agaagggtgga 360  
 gctgcaggag ctgaatgacc gcttcgcca ctacatcgac aagggtgcgt tcctggagca 420  
 gcagaataag atcctgctgg ccgagctcga gcagctcaag ggccaaggca agtcgcgcct 480  
 gggggacctc tacgaggagg agatgcggga gctgcgcggc cagggtggacc agctaaccac 540  
 cgacaaagcc cgcgtcgagg tggagcgcca caacctggcc gaggacatca tgcgcctccg 600  
 ggagaaattg caggaggaga tgcttcagag agaggaagcc gaaaacaccc tgcaatcttt 660  
 cagacaggat gttgacaatg cgtctctggc acgtcttgac cttgaacgca aagtggaatc 720  
 tttgcaagaa gagattgcct ttttgaagaa actccacgaa gaggaaatcc aggagctgca 780  
 ggctcagatt caggaacagc atgtccaaat cgatgtggat gtttccaagc ctgacctcac 840  
 ggctgccctg cgtgacgtac gtcagcaata tgaaagtgtg gctgccaaga acctgcagga 900  
 ggcagaagaa tgggtacaaat ccaagtttgc tgacctctct gaggctgcca accggaacaa 960  
 tgacgccctg cgccaggcaa agcaggagtc cactgagtag cggagacagg tgcagtccct 1020  
 cacctgtgaa gtggatgccc ttaaaggaa caatgagtag ctggaacgcc agatgcgtga 1080  
 aatggaagag aactttgccc ttgaagctgc taactaccaa gacactattg gccgcctgca 1140  
 ggatgagatt cagaatatga aggaggaaat ggctcgccac cttcgtgaat accaagacct 1200  
 gctcaatgtt aagatggccc ttgacattga gattgccacc tacaggaagc tgctggaagg 1260  
 cgaggagagc aggttttctc tgccctcttc aaacttttcc tcctgaacc tgagggaaac 1320  
 taatctggat tccctccctc tgggtgatac cactcaaaa aggacacttc tgattaagac 1380  
 ggttgaaact agagatggac aggttatcaa cgaaacttct cagcatcacg atgacctga 1440  
 ataaaaattg cacacactca gtgcagcaat atattaccag caagaataaa aaagaaatcc 1500  
 atatcttaaa gaaacagctt tcaagtgcct ttctgcagtt tttcaggagc gcaagataga 1560  
 tttggaatag gaataagctc tagttcttaa caaccgacac tcctacaaga tttagaaaaa 1620  
 agttttacaac ataattagtt ttacagaaaa atcttggtgt agaatacttt ttaaaaggta 1680  
 ttttgaatac cattaaaact gctttttttt ttccagcaag tatccaacca acttggttct 1740  
 gcttcaataa atcttttgaa aaacta 1766

<210> 3  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 linker peptide

<220>  
 <221> MOD\_RES  
 <222> (4)  
 <223> Leu-Dau

<400> 3  
 Ala Leu Ala Leu  
 1

<210> 4  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
linker peptide

<220>  
<221> MOD\_RES  
<222> (4)  
<223> Gly-Dau

<400> 4  
Gly Phe Leu Gly  
1

<210> 5  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
linker peptide

<400> 5  
Leu Ala Leu Ala  
1